Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

This study has been completed.
Arriva Pharmaceuticals, Inc.
Information provided by:
Baxalta US Inc. Identifier:
First received: September 8, 2005
Last updated: June 26, 2015
Last verified: October 2006
The purpose of this randomized, double-blind, placebo-controlled study is to evaluate the short-term safety of inhaled recombinant alpha 1-antitrypsin (rAAT) in subjects with alpha 1-antitrypsin deficiency. The subjects are randomized to receive placebo or one of 4 doses of rAAT. The 4 doses are tested in a consecutive manner from lowest to highest.

Condition Intervention Phase
Alpha 1-antitrypsin Deficiency
Drug: Aerosolized, Recombinant Alpha 1-Antitrypsin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency

Resource links provided by NLM:

Further study details as provided by Baxalta US Inc.:

Study Start Date: January 2003
Estimated Study Completion Date: October 2003

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female 18 years of age or older
  • Endogenous plasma AAT levels < 11 µM (< 80 mg/dL)
  • Baseline forced expiratory volume at one second (FEV1) that is >= 50% of predicted, measured 30 minutes after a short-acting inhaled bronchodilator
  • Baseline arterial oxygen percent saturation (SaO2) within the normal limits for the individual study site
  • For subjects receiving an inhaled corticosteroid, β-2 agonist (eg, albuterol via metered dose inhaler [MDI]) or anticholinergic bronchodilator (eg, ipratropium bromide), treatment on a stable dose for at least 14 days prior to randomization
  • If female of childbearing potential, negative urine pregnancy test within 3 days prior to randomization and agreement to employ adequate birth control measures
  • No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed no more than 7 days prior to randomization
  • Baseline laboratory results, obtained no more than 7 days prior to randomization, meeting the following criteria:
  • Serum aspartate transaminase (AST) and alanine transaminase (ALT) <= 2 times upper limit of normal range (ULN)
  • Serum total bilirubin <= 2 times ULN
  • < 2+ proteinuria on urine dipstick
  • Serum creatinine <= 1.5 times ULN
  • Absolute neutrophil count >= 1500 cells/mm3
  • Hemoglobin >= 10.0 g/dL
  • Platelet count >= 100,000/mm3
  • Signed informed consent

Exclusion Criteria:

  • Clinically significant pulmonary impairment, other than emphysema and/or chronic bronchitis
  • Clinically significant cardiac, hemostatic, or neurologic impairment, or other significant medical condition that, in the opinion of the investigator, would affect subject safety or compliance
  • Psychiatric or cognitive disturbance or illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance
  • Acute exacerbation of emphysema (as defined in Section 8.5.10) within 28 days prior to randomization
  • Pregnancy or lactation
  • Known history of allergy to yeast products
  • Medical history precluding the use of epinephrine or other rescue medication for treatment of anaphylaxis
  • Use of antihistamines within 7 days prior to randomization
  • Use of oral steroids, beta-blockers, or tricyclic antidepressants within 28 days prior to randomization
  • Use of another investigational drug or investigational device within 28 days prior to randomization
  • Any upper or lower respiratory infection within 28 days prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00161707

United States, Colorado
National Jewish Medical and Research Center
Denver, Colorado, United States, 80206
United States, Florida
Shands Hospital at the University of Florida
Gainesville, Florida, United States, 32610
United States, Ohio
Cleveland Clinic Foundation, Department of Pulmonary and Critical Care Medicine
Cleveland, Ohio, United States, 44195
United States, Texas
The University of Texas Health Science Center at Tyler
Tyler, Texas, United States, 75708-3154
Sponsors and Collaborators
Baxalta US Inc.
Arriva Pharmaceuticals, Inc.
Principal Investigator: Mark Brantly, MD Shands Hospital at the University of Florida
  More Information Identifier: NCT00161707     History of Changes
Other Study ID Numbers: 410103
Study First Received: September 8, 2005
Last Updated: June 26, 2015

Additional relevant MeSH terms:
Alpha 1-Antitrypsin Deficiency
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Pathologic Processes
Alpha 1-Antitrypsin
Protein C Inhibitor
Trypsin Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017